We are live on
!
Find out more
YMAB
Y-mAbs Therapeutics
YMAB
YMAB
Delisted
YMAB was delisted on the 15th of September, 2025.
Fund managers haven’t disclosed any holdings of YMAB yet.
YMAB Hedge Fund Activity: Q4 2025 in Review
0 of the 8,228 institutional investors tracked by Wall St. Rank reported a position in Y-mAbs Therapeutics (YMAB) for Q4 2025, worth a combined $0 — down 100% from $78.3K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of YMAB and 0 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Brooklyn Investment Group, exiting entirely with an estimated $75.5K sold.
- 0 institutional investors held Y-mAbs Therapeutics (YMAB) as of Q4 2025, down from 2 in Q3 2025.
- Funds reported $0 of Y-mAbs Therapeutics stock for Q4 2025, down 100% quarter-over-quarter.
- 0 funds opened new Y-mAbs Therapeutics positions in Q4 2025 and 2 closed out, a net change of -2 holders.
- The largest Y-mAbs Therapeutics seller in Q4 2025 was Brooklyn Investment Group, an estimated $75.5K sold.
Based on aggregated 13F filings for Q4 2025.